◆英語タイトル:UCB SA (UCB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7196
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company’s key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn’s disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.
UCB SA (UCB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
UCB SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
UCB SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
UCB SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
UCB SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
UCB SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
UCB SA, Medical Equipment, Deal Details 10
Venture Financing 10
Ceribell Raises USD35 Million in Series B Financing 10
Partnerships 11
Partners HealthCare System and UCB Enter into Agreement 11
MC10 Enters into Agreement with UCB 12
Evogen Enters into Agreement with UCB 13
MC10 Enters into Co-Development Agreement with UCB 14
Allium Medical Solutions Enters Into Distribution Agreement With Meizler UCB Biopharma For Urological Stents 15
King’s College London Enters Into Licensing Agreement with UCB 16
Acquisition 17
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 17
UCB Acquires 51% Stake In Meizler Biopharma 18
UCB SA – Key Competitors 19
UCB SA – Key Employees 20
UCB SA – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Joint Venture 24
Recent Developments 25
Strategy And Business Planning 25
May 03, 2018: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home 25
Financial Announcements 26
Jul 26, 2018: UCB half year report 2018: UCB continues its growth path 26
Apr 25, 2018: UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook 28
Feb 22, 2018: UCB Full Year Report 2017 30
Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 31
Jul 27, 2017: UCB with a strong first half year 2017 – giving rise to the financial outlook for 2017 32
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 35
Corporate Communications 36
Mar 24, 2017: UCB General Meeting on 27 April 2017 36
Other Significant Developments 37
May 07, 2018: Partnership with Science 37: helping UCB to improve patient experience 37
Apr 26, 2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development 38
Jan 05, 2017: MC10 and UCB Complete Landmark Pharmaceutical / Technology Collaboration Evaluating Patient Monitoring in Parkinson’s 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
UCB SA, Medical Equipment, Key Facts, 2017 2
UCB SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
UCB SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
UCB SA, Medical Equipment Deals By Type, 2012 to YTD 2018 6
UCB SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
UCB SA, Deals By Market, 2012 to YTD 2018 8
UCB SA, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Ceribell Raises USD35 Million in Series B Financing 10
Partners HealthCare System and UCB Enter into Agreement 11
MC10 Enters into Agreement with UCB 12
Evogen Enters into Agreement with UCB 13
MC10 Enters into Co-Development Agreement with UCB 14
Allium Medical Solutions Enters Into Distribution Agreement With Meizler UCB Biopharma For Urological Stents 15
King’s College London Enters Into Licensing Agreement with UCB 16
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 17
UCB Acquires 51% Stake In Meizler Biopharma 18
UCB SA, Key Competitors 19
UCB SA, Key Employees 20
UCB SA, Subsidiaries 21
UCB SA, Joint Venture 24
List of Figures
UCB SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
UCB SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
UCB SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
UCB SA, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
UCB SA, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
UCB SA, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
UCB SA, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
UCB SA, Medical Equipment, Deals by Market, 2012 to YTD 2018 8